Results 131 to 140 of about 811,174 (190)

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

open access: yes
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta   +3 more
wiley   +1 more source

Remibrutinib as a Therapeutic Option for Solar Urticaria

open access: yes
Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 6, November 2026.
Joshua Mijares   +3 more
wiley   +1 more source

Targeting Bruton’s Tyrosine Kinase (BTK) in Autoimmunity: Achievements, Opportunities and Challenges

open access: yesDrug Design, Development and Therapy
Sebastian Torke,1,* Sarah Dybowski,2,* Martin S Weber2– 41Experimental and Clinical Research Center, Charité-Medical Center Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; 2Department of Neurology, University ...
Torke S, Dybowski S, Weber MS
doaj  

BTK Inhibitors: Past, Present, and Future

open access: yesTrends in Pharmacological Sciences
Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for B cell lymphomas such as chronic lymphocytic leukemia (CLL). The first-in-class BTK inhibitor ibrutinib has recently been succeeded by covalent BTK inhibitors that are safer but still face challenges of resistance mutations.
Skye Montoya   +2 more
exaly   +4 more sources

Evolution of BTK inhibitors [PDF]

open access: yesLynchburg Journal of Medical Science
The purpose of this clinical review evaluates the evolution of bruton’s tyrosine kinase (BTK) inhibitors in becoming the standard of care in treating chronic lymphocytic leukemia (CLL). The first-generation BTK inhibitor ibrutinib has demonstrated superior efficacy over traditional chemotherapy in several randomized clinical trials in terms of ...
Mathew, Dena
openaire   +2 more sources

Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective

open access: yesInternational Journal of Molecular Sciences, 2021
In the past few years, Bruton’s tyrosine Kinase (Btk) has emerged as new target in medicinal chemistry. Since approval of ibrutinib in 2013 for treatment of different hematological cancers (as leukemias and lymphomas), two other irreversible Btk ...
Chiara Brullo   +2 more
exaly   +3 more sources

Pirtobrutinib After a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia [PDF]

open access: yesNew England Journal of Medicine, 2023
In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 ...
Chan Yoon Cheah   +2 more
exaly   +2 more sources

Cardiotoxicity of BTK inhibitors: ibrutinib and beyond

Expert Review of Hematology, 2022
The development of Brutons Tyrosine Kinase (BTK) inhibitors has transformed the treatment of B-cell malignancies and other non-malignant conditions. Management of the unique cardiotoxic profile of these agents requires prompt recognition and a multi-disciplinary approach.The increasing indications and addition of newer agents to clinical practice and ...
Bradley W. Christensen   +2 more
openaire   +2 more sources

On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors

Cancer Discovery, 2022
Abstract Resistance to noncovalent BTK inhibitors is mediated by non-C481 BTK and PLCγ2 mutations.
openaire   +2 more sources

Home - About - Disclaimer - Privacy